Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. (NASDAQ: EXOZ) is a biotechnology company that publicly reports on developments in its AI-enhanced, cell-free biomanufacturing platform. The company focuses on exozymes, which it defines as advanced enzymes engineered to operate in bioreactors without living cells, transforming sustainable feedstock into essential chemicals, nutraceuticals, medicines, biofuels, and other valuable biochemicals.
The EXOZ news feed highlights updates that the company shares through press releases and investor communications. These include technical milestones such as the reported 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production with over 99% conversion from feedstock to product using its exozyme-based process, as well as earlier progress going from concept to gram-scale NCT production with high yield and purity. News items also cover the evolution of its programs around NCT, santalene, and other highly valuable natural product molecules.
Investors and followers of eXoZymes can use the news page to review announcements about quarterly update webinars, investor conference presentations, and participation in industry initiatives. The company has issued news about being selected as a core industry partner in an NSF-funded initiative for modular cell-free biomanufacturing, and about leadership roles in BioMADE governance committees related to cell-free enzyme pathways and bioindustrial manufacturing.
In addition, the EXOZ news stream includes items on management appointments and commentary from company leaders on topics such as AI in life sciences, synthetic biology scaling challenges, and the concept of exozymes as next generation biomanufacturing. By following this page, readers can see how eXoZymes presents its scientific progress, platform maturation, and communication with the investment community over time.
eXoZymes (NASDAQ:EXOZ) and its spinout NCTx have achieved a significant biomanufacturing breakthrough, producing 4 grams of N-trans-caffeoyltyramine (NCT) with over 99% purity and 96% yield using their AI-driven exozymes platform.
The project progressed from concept to gram-scale production in just 5 months, significantly faster than traditional synthetic biology approaches. NCT, naturally found in trace amounts in hemp seeds (less than 0.014%), has shown potential benefits for liver fat metabolism, gut barrier function, and mitochondrial activity.
The company plans to scale production 100X over the next six months and is preparing for GMP pilot scale production in 2026. The bioactive ingredients market represents a $216 billion opportunity with 7.6% CAGR globally. eXoZymes is actively seeking early access partners under material transfer agreements.
eXoZymes (NASDAQ:EXOZ) and its spinout NCTx have achieved a significant biomanufacturing breakthrough in producing N-trans-caffeoyltyramine (NCT), a bioactive compound. The company successfully went from concept to gram-scale production in just 5 months, achieving a 96% reaction yield.
This milestone addresses the challenge of sourcing NCT, which naturally occurs in trace amounts (less than 0.014%) in hemp seeds. The breakthrough enables commercial viability in the $216 billion functional food market, growing at 7.6% CAGR. NCT shows promise in supporting liver fat metabolism, gut barrier function, and mitochondrial activity, with preclinical studies demonstrating enhanced fat breakdown and potential NAFLD/MASLD treatment applications.
eXoZymes (NASDAQ:EXOZ) has been selected as a core industry partner in the $9.2 million NSF-funded Meta-PURE initiative, led by Georgia Tech. The company will receive a $3 million share of the total funding to develop a cell-free ATP-generating module that will serve as a power source for various chemical production processes.
As the key industrial partner, eXoZymes will focus on creating a standardized, plug-and-play cell-free power plant system that enables faster reaction times and greater product yields. The company will also develop a production module for santalene, a high-value fragrance compound used in aromatherapy and traditional medicine.
eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes, was featured on the Grow Everything podcast discussing their innovative biomanufacturing platform. CEO Michael Heltzen highlighted how their exozymes technology enables sustainable chemical production outside living cells, offering advantages over traditional cell-based synthetic biology.
The company announced their first spinout, NCTx, which focuses on producing NCT, a rare small molecule with potential treatment applications for non-alcoholic fatty liver disease (NAFLD). eXoZymes is actively pursuing partnerships for co-development and licensing, with current projects including nutraceuticals, pharmaceuticals, and Sustainable Aviation Fuels backed by DoE and DoD funding.
eXoZymes (NASDAQ:EXOZ), a company developing AI-engineered enzymes for sustainable feedstock transformation, announced its Q1 2025 financial results and operational updates. The company reached a significant milestone with the launch of its subsidiary NCTx, focused on commercializing the eXoZymes platform with N-trans-caffeoyltyramine (NCT).
Financial highlights include operating expenses of $1.95 million, primarily attributed to expanded R&D and leadership hiring. The company maintains $8.51 million in cash and cash equivalents, sufficient to fund operations into 2026. As a pre-revenue company, eXoZymes continues to focus on efficient execution and capital allocation while progressing toward value inflection points.
eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes for sustainable feedstock transformation into nutraceuticals, medicines, and essential chemicals, has announced a webinar scheduled for Monday, May 12, 2025, at 5:00 PM Eastern Time. The event will cover the company's first quarter 2025 results and provide updates on their newly formed subsidiary, NCTx.
CEO Michael Heltzen will lead the presentation alongside management team members, discussing recent developments, ongoing initiatives, and upcoming milestones. The webinar will include a Q&A session and can be accessed through pre-registration or the company's investor relations website.
eXoZymes (NASDAQ:EXOZ) has launched a new subsidiary, NCTx, focused on developing N-trans-caffeoyltyramine (NCT), a rare plant compound with potential applications in liver and gut health. Using eXoZymes' AI-driven platform, NCTx has developed a proprietary approach to biomanufacture NCT, overcoming previous sourcing limitations where it was only found in trace amounts (less than 0.014%) in hemp seeds.
The company completed proof of concept in just 6 weeks and established the subsidiary in 12 weeks, demonstrating unprecedented speed in bio-manufacturing innovation. Pre-clinical studies show NCT's potential in treating Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over 30% of the global population. The target market for bioactive ingredients in functional food is valued at $216 billion with a 7.6% CAGR globally.
eXoZymes Inc. (NASDAQ: EXOZ) is featured as the cover story in the April 2025 issue of GEN Biotechnology, introducing the scientific definition of 'exozymes' to clarify the cell-free biomanufacturing field. The peer-reviewed Open Access paper titled 'Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space' aims to distinguish cell-free biomanufacturing from other cell-free technologies.
The paper, co-authored by experts from institutions including NREL, UCLA, Caltech, and University of Colorado Boulder, defines exozymes as industrial biomanufacturing methods that produce chemicals without using living cells. The terms 'exozymes' and 'exozyme systems' are introduced to facilitate better understanding among investors, scientists, and the public, with no trademarks filed to ensure free usage by the scientific community.
eXoZymes (NASDAQ: EXOZ) has launched BioClick, a groundbreaking enzyme engineering initiative supported by a $300K NIH grant. The project focuses on enhancing group transfer reactions in enzyme engineering, particularly prenylation, to improve drug development and biomanufacturing processes.
BioClick introduces what the company calls the 'third generation of enzyme engineering: Artificial Evolution', following directed evolution and rational protein design. The platform incorporates AI and high-throughput screening capabilities, enabling simultaneous testing of thousands of enzyme variations using mass spectrometry and advanced data analysis algorithms.
The technology aims to accelerate the development of new drugs and improve existing ones by enabling the creation of previously inaccessible small molecules. The project specifically targets the enhancement of drug compounds' functionality and effectiveness through precise molecular modifications.
eXoZymes (NASDAQ: EXOZ) has appointed Damien Perriman as Chief Commercial Officer (CCO) in a newly created role. Perriman brings over 20 years of experience in commercializing biotechnologies across nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals markets.
Previously holding commercial leadership positions at Genomatica (Geno) and Gevo, Perriman also serves as Chairman of Danish biotech startup Cellugy. The appointment aligns with eXoZymes' strategic focus on scaling and commercializing biosolutions for sustainable feedstock transformation into essential chemicals, medicines, and biofuels.
The company will discuss this appointment during their Q4 and full-year 2024 results conference call scheduled for 4:30 PM Eastern / 1:30 PM Pacific.
FAQ
What is the current stock price of eXoZymes (EXOZ)?
What is the market cap of eXoZymes (EXOZ)?
